

A Dialectological Pharmacovigilance Study of the Rational Pharmacotherapeutic Appraisal of the Combination Therapies of 50 mg or 75 mg Remogliflozin with 500 mg Metformin, and an Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction Evaluation: A Research Series, in Evidence-Based Medicine

Moumita Hazra^{1,2,3,4}

¹ Associate Professor, Head of Department In Charge, Department of Pharmacology, Pharmaco-Haemo-Materio-Vigilance Specialist, Pharmacovigilance Committee, Mamata Medical College and Hospitals, Telangana, India.

² Former Associate Professor, Head of Department In Charge, Department of Pharmacology, Rama Medical College Hospital and Research Centre, Rama University, Uttar Pradesh, India.

³ Medical Director, Medical Superintendent, Consultant Multi-Specialist Clinical Pharmacological and Diabetological Physician, Consultant Clinical Pathologist, Hazra Nursing Home, Hazra Polyclinic And Diagnostic Centre, Dr. Moumita Hazra's Polyclinic And Diagnostic Centre, West Bengal, India.

⁴ Former Assistant Medical Director, GIOSTAR Institute of Regenerative Medicine Institutes, Hospitals and Laboratories, New Delhi, India, United States of America, World.

ABSTRACT

INTRODUCTION

Remogliflozin, a selective insulin independent sodium glucose co - transporter subtype 2 (SGLT2) inhibitor, inhibits reabsorption of renal glucose, lowers blood sugar, and causes glucosuria, in type II diabetes mellitus patients. Metformin, as a combination anti-diabetic drug, lowers serum glucose levels; by the activation of 5' Adenosine Monophosphate (AMP) activated protein kinase.

OBJECTIVES

The objective of this Evidence-Based Medicine research series was the rational pharmacotherapeutic appraisal of the diabetological pharmacovigilance of the combination therapies of 50 mg or 75 mg remogliflozin with 500 mg metformin among type II diabetics, in tertiary care medical college hospitals, along global pharmacoepidemiology, and an anti - diabetic tertiary medical healthcare patient satisfaction evaluation.

METHODS

125 new early moderate grade type II diabetes mellitus patients were prescribed oral metformin 500 mg once daily for 30 days. Then, 100 diabetics uncontrolled with metformin monotherapy, were prescribed oral 50 mg remogliflozin with 500 mg metformin once daily, for 15 days; who were subsequently prescribed oral 75 mg remogliflozin with 500 mg metformin once daily for 15 days. The safety assessment, along with blood sugar and HbA1c levels and urine routine examination, on day 0, day 30, day 46, day 60, and further follow - up, were recorded and statistically analysed. An anti - diabetic tertiary medical healthcare patient satisfaction evaluation was also performed by patient response to different attributes of anti-diabetic treatment.

RESULTS

The adverse effects with the combination therapy of 50 mg remogliflozin with metformin and the combination therapy of 75 mg remogliflozin with metformin were statistically non - significant; hence both were safe and tolerable. All the patients were satisfied with each anti-diabetic medical healthcare attribute.

CONCLUSION

The combination therapy of 50 mg remogliflozin and metformin as well as the combination therapy of 75 mg remogliflozin and metformin were safe and tolerable. There was ample anti - diabetic medical healthcare satisfaction.

KEYWORDS

Biguanides, Metformin, Sodium glucose co-transporter subtype 2 inhibitors, Remogliflozin, Pharmacovigilance, Dialectology, and Anti - diabetic medical healthcare patient satisfaction.

Corresponding Author:

Dr. Moumita Hazra, Polyclinic And Diagnostic Centre, Hazra Nursing Home, Hazra Polyclinic And Diagnostic Centre, Jagadishpur Road, Opposite Domjur Football Ground, P.O. Domjur, Dist. Howrah, West Bengal, India.

Email:

drmoumitahazra.198017thjune@gmail.com

om

How to Cite This Article:

Moumita H. A Dialectological Pharmacovigilance Study of the Rational Pharmacotherapeutic Appraisal of the Combination Therapies of 50 mg or 75 mg Remogliflozin with 500 mg Metformin, and an Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction Evaluation: A Research Series, in Evidence-Based Medicine. J Evid Based Med Healthc 2022;9(03):1-7.

Received: 01-02-2022;

Manuscript No: JEBMH-22-53055;

Editor assigned: 04-02-2022;

PreQC No. JEBMH-22-53055 (PQ);

Reviewed: 09-02-2022;

QC No. JEBMH-22-53055;

Revised: 15-02-2022;

Manuscript No. JEBMH-22-53055 (R);

Published: 28-02-2022;

DOI: 10.18410/jebmh/2022/02.

Copyright © 2022 Moumita H. This is an open access article distributed under Creative Commons Attribution License [Attribution 4.0 International (CC BY 4.0)]

INTRODUCTION

The American Association of Clinical Endocrinologists (AACE) guidelines for T2DM management, suggest lifestyle therapy, medically assisted weight loss, and individual goals of achieving hemoglobin A1C (HbA1C) level of $\leq 6.5\%$. The determining factors behind the choice of antidiabetic drugs are the different patient characteristics, like glycemic index, weight, lifestyle, co-morbidities, and undesirable side effects of pharmacy - therapeutic management.

With remogliflozin, a selective insulin independent sodium glucose co - transporter subtype 2 (SGLT2) inhibitor, the management of type II diabetes mellitus has taken a quantum leap, producing anti - hyperglycaemic activity in both diabetes mellitus type II, and insulin resistant patients, when given in monotherapy or in combination with metformin. Remogliflozin inhibits glucose reabsorption in the kidney, thus lowering blood sugar, and causing glucosuria. Clinical guidelines recommend SGLT2 inhibitors as one of the second-line pharmacological therapeutic approaches, following metformin failure or intolerance. SGLT2 inhibitors cause wider benefits like adequate glycaemic control, significant improvements in haemoglobin A1c, insulin sensitivity and β cell function, weight loss, blood pressure reduction, cardiovascular and renal protection by significantly increasing HDL cholesterol, decreasing LDL cholesterol, reducing albuminuria and delaying the progression of nephropathy. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) suggest the therapeutic use of SGLT2 inhibitors for patients with diabetic co - morbidities like cardiovascular disease (including heart failure, and atherosclerotic cardiovascular disease) and chronic kidney disease.^{1,2}

Metformin has considerably improved outcomes, as a combination anti-diabetic drug, with pleotropic effects on glucose metabolism. Metformin inhibits hepatic gluconeogenesis in a substrate selective manner, through the transcription, allosteric, substrate availability or redox mechanisms; and by metformin inhibition of complex I leading to reductions in hepatocellular energy charge and other downstream events (e.g., Adenosine Monophosphate-Activated Protein Kinase (AMPK) activation, fructose 1,6-bisphosphatase inhibition, inhibition of glucagon signaling). It overcomes insulin resistance, and lowers serum glucose levels; by the activation of 5' Adenosine Monophosphate (AMP) activated protein kinase. Metformin alters the cellular redox balance, and the increased cytosolic redox state, due to the inhibition of glycerol-3-phosphate dehydrogenase by metformin. This is observed at clinically relevant concentrations, and is the only proposed mechanism of action that predicts substrate selective (glycerol and lactate) inhibition of hepatic gluconeogenesis. Metformin is both effective and inexpensive, and may reduce the risk of cardiovascular events and death. It has beneficial effects on HbA1C and weight; and a well - established safety profile.^{1, 3, 4}

The commonly associated side effects with oral anti - diabetic agents are hypoglycaemia, weight gain due to hyperinsulinemia, gastrointestinal symptoms, and hepato - renal toxicity. The critical effects under consideration for the clinical rationale of the anti-diabetic drugs are their potential for hypoglycaemia, weight gain, and long term side effects. This augmentation of adverse effects demands a safer antidiabetic agent. Therefore, this study was conducted as an endocrinological pharmacovigilance study to evaluate the safety involving the clinical therapeutic prescription of anti - diabetic combination therapies, with the escalating doses of

remogliflozin : 50 mg remogliflozin and 500 mg metformin, which was subsequently followed by 75 mg remogliflozin and 500 mg metformin, once daily. The successful synergistic effects of these combination therapies and the better drug dose combination regimens, intend to decrease the occurrence of adverse effects, with increased safety and tolerability, thus benefiting the treatment of diabetes mellitus type II. A patient-centered approach was used to guide the choice of pharmacologic agents. The effects of the cardiovascular and renal comorbidities, efficacy, hypoglycaemia risk, impact on weight, cost, risk for side effects, and patient preferences, were also taken into consideration.¹⁻⁴

Objectives

The objective of this Evidence-Based Medicine research series was the rational pharmacotherapeutic appraisal of the diabetological pharmacovigilance of the combination therapies of 50 mg or 75 mg remogliflozin with 500 mg metformin among type II diabetics, in tertiary care medical college hospitals, along global pharmacoepidemiology, and an anti-diabetic tertiary medical healthcare patient satisfaction evaluation.

METHODS

Ethical Approval

At first, the Institutional Ethics Committee clearance and approval was taken. The study was conducted in accordance with the ethical principles of Declaration of Helsinki and good clinical practices contained within the international council for harmonization of technical requirements for pharmaceuticals for human use (ICH - E6 and ICH - E17), and in compliance with the regulatory requirements. An informed consent was obtained from each patient.

Inclusion Criteria

The inclusion criteria were as follows:

- (i) Patients of any gender, (ii) Patients within 35 and 60 years, (iii) Patients of around 60 kg average body weight, (iv) Patients presenting with new type II diabetes mellitus, of early moderate grade, (v) Type II diabetes mellitus American Diabetes Association diagnosis criteria, (vi) Co - operative and conscious patients, (vii) Patients willing to undergo all pre and post- treatment investigations and willing to complete the entire course of treatment, (viii) Patients who have given consent and are willing to go for a follow-up, (ix) Patients not taking any previous anti-diabetic drug, (x) Patients not taking any concomitant medication.

Exclusion Criteria

The exclusion criteria were as follows:

- (i) Uncooperative or unconscious patients, (ii) Patients below 35 and above 60 years, (iii) Patients presenting with any grade other than early moderate grade of diabetes, (iv) Patients with a history of hypersensitivity to any of the study drugs, (v) Patients with high risk diseases or co-morbidities, (vi) Cardiac, renal or any other associated complications or co-morbidities, (vii) Any chronic disease intervening with the study data, (x) Pregnant or lactating women, (xi) Pediatric or geriatric patients, (xii) Other associated medical illness or disorders, like uro - genital tract infections, having impact on study results, (xiii) Female patients using hormonal contraceptives.

Study Design

A global, multi - center, prospective, randomized, open-labelled study.

Study Population

The study population was 150 new type II diabetes mellitus patients, of early moderate grade.

Place of Study

The place of research study and the compilation of the study literature were the Departments of Pharmacology, Clinical Pharmacology, Molecular Pharmacology, Endocrinology, Diabetology and Metabolic Medicine, Pharmacovigilance, Rational Pharmacotherapeutics, Evidence Based Medicine, Clinical Medicine, Clinical Pathology and Pathology, in Hazra Polyclinic and Diagnostic Centre, Mamata Medical College and Hospitals, Rama Medical College Hospital and Research Centre, GIOSTAR Institute of Regenerative Medicine Institutes, Hospitals and Laboratories, Hazra Nursing Home, and Dr. Moumita Hazra's Polyclinic And Diagnostic Centre.

Study Period

The study period was 9 months, from May, 2021 to February, 2022.

Study Procedure

125 new type II diabetes mellitus patients, of early moderate grade, were prescribed oral metformin 500 mg (8.40 mg/kg), once daily, for 30 days.

After 1 month, from these 125 patients, 25 diabetic patients: (i) Who had achieved adequate glycaemic control with metformin monotherapy, or (ii) Who were lost to follow - up, or (iii) Who had dropped out due to adverse effects, or (iv) Who had withdrawn voluntarily, were excluded from the study. The remaining 100 patients, whose glycaemic index was uncontrolled with metformin monotherapy, were prescribed oral 50 mg (0.84 mg / kg) remogliflozin once daily with 500 mg metformin once daily for 15 days; and were subsequently prescribed oral 75 mg (1.25 mg / kg) remogliflozin once daily with 500 mg metformin once daily for 15 days.

The patients' characteristics, diabetic symptoms assessment, patients' disease and disease - related history were recorded with a proforma. Then, thorough general physical examination and systemic examination were performed on the patients under study. The relevant blood, urine and other investigations were done to confirm the progressing health status of the patients being treated. The efficacy assessment was done, by recording the fasting and the post - prandial blood sugar level, HbA1c level and urine routine examination findings including sugar and albumin levels and microscopy, (a) At baseline level on day 0; (b) After administering metformin monotherapy at day 30; (c) After administering the combination therapy at day 46; (d) After administering the combination therapy at day 60; and (d) Further follow - up.

The safety assessment was done with an Adverse Event Case Report Form, by the monitoring of adverse drug reactions, like hypoglycaemia, weakness, gastrointestinal disturbances, abdominal pain, and upper respiratory tract infections, after metformin monotherapy, from day 0 to day 30. Then, the safety was assessed by monitoring any adverse reaction, like genital mycotic infections, urinary tract infections, pyrexia, headache, dizziness, nausea, gastrointestinal disturbances, hypoglycaemia, weakness or abdominal pain, after the combination therapy of 50 mg remogliflozin once daily with 500 mg metformin once daily,

from (i) Day 30 to day 46; after the combination therapy of 75 mg remogliflozin once daily with 500 mg metformin once daily; from (i) Day 46 to day 60; and (ii) Further follow - up.

The anti - diabetic medical healthcare patient satisfaction was evaluated by the response of the patients to the different attributes, like immediate treatment delivery, appropriate and convenient investigations and treatment, quickly controlled diabetes, safe and tolerable treatment, easily accessible medications, convenient administration of medications, and maintenance of symptom - free controlled diabetic period. These observations were recorded and thoroughly analysed.

Statistical Analysis

At the study completion point, the observations recorded in this study, were statistically analysed by the Test of significance with p values, with subsequent tabular representations.

RESULTS

The demographic characteristics of the patients, in this study, were comparable. Among 125 new type II diabetes mellitus patients, of early moderate grade, receiving metformin monotherapy for 1 month, 25 diabetic patients : (i) Who had achieved adequate glycaemic control with metformin monotherapy, or (ii) Who were lost to follow - up, or (iii) Who had dropped out due to adverse effects, or (iv) Who had withdrawn voluntarily, were excluded from this study. The remaining 100 patients, whose glycaemic index was uncontrolled with metformin monotherapy, received 50 mg remogliflozin with metformin combination therapy, for 15 days, which was subsequently followed by the combination therapy of 75 mg remogliflozin with metformin, for 15 days. These patients had completed the study thoroughly, with no adverse effects related drop - out patients, lost to follow-up patients or voluntarily withdrawn patients.

The combination therapies of 50 mg or 75 mg of remogliflozin and metformin were observed to be safe, which had controlled type II diabetes mellitus among new patients, with significant decrease in the blood sugar levels and the HbA1c levels, within 2 months.

Adverse Effects	Number of Patient Occurrence	P Value
Genital mycotic infections	0	non-significant
Urinary tract infections	0	non-significant
Pyrexia	0	non-significant
Headache	0	non-significant
Dizziness	0	non-significant
Nausea	0	non-significant
Gastrointestinal disturbances	0	non-significant
Hypoglycemia	0	non-significant
Weakness	0	non-significant
Abdominal pain	0	non-significant

Table 1: The Occurrence of Adverse Effects with 50 mg Remogliflozin and 500 mg Metformin Combination Therapy.

Table 1 depicts the occurrence of adverse effects with 50 mg remogliflozin and 500 mg metformin combination therapy.

DISCUSSION

Adverse Effects	Number of Patient Occurrence	P Value
Genital mycotic infections	0	non-significant
Urinary tract infections	0	non-significant
Pyrexia	0	non-significant
Headache	0	non-significant
Dizziness	0	non-significant
Nausea	0	non-significant
Gastrointestinal disturbances	0	non-significant
Hypoglycemia	0	non-significant
Weakness	0	non-significant
Abdominal pain	0	non-significant

Table 2 : The Occurrence of Adverse Effects with 75 mg Remogliflozin and 500 mg Metformin Combination Therapy.

Table 2 depicts the occurrence of adverse effects with 75 mg remogliflozin and 500 mg metformin combination therapy.

There were no adverse effects observed with the combination therapy of 50 mg remogliflozin with metformin as well as the combination therapy of 75 mg remogliflozin with metformin, which were statistically non - significant. The combination therapy of 50 mg remogliflozin with metformin and the combination therapy of 75 mg remogliflozin with metformin were observed to be safe and tolerable.

All the global patients were satisfied with the different attributes of anti - diabetic tertiary medical healthcare provided, like immediate treatment delivery, appropriate convenient investigations and treatment, quickly controlled diabetes, safe and tolerable treatment, early accessible medications, convenient administration of medications and maintenance of symptom-free controlled diabetic period, as depicted in Table 3.

Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction Attributes	Patient's Response : Satisfied	Patient's Response : Indeterminate	Patient's Response : Unsatisfied
Immediate treatment delivery	Satisfied	-	-
Appropriate and convenient investigations and treatment	Satisfied	-	-
Quickly controlled diabetes	Satisfied	-	-
Safe and tolerable treatment	Satisfied	-	-
Easily accessible medications	Satisfied	-	-
Convenient administration of medications	Satisfied	-	-
Maintenance of symptom-free controlled diabetic period	Satisfied	-	-

Table 3 : Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction.

Gliflozin drugs, the sodium - glucose co - transporter 2 inhibitors, are the newly developed class of oral hypoglycaemic agents used for the treatment of the type - II diabetes mellitus. This drug category was approved by the food and drug administration for the treatment of diabetes and it has a very unique mechanism of action. The SGLT (sodium - glucose transport) proteins are the macromolecules causing reabsorption of the filtered glucose from the proximal convoluted tubule (PCT) part of the nephron. The significance lies in the fact that these proteins work independent of insulin. Probably the SGLT proteins occur in the nephron and the large intestine. The two main types of SGLT proteins are SGLT 1 and SGLT 2. The SGLT 1 proteins occur in PCT of nephron as well as in the large intestine. The SGLT 2 proteins occur only at PCT part of the nephron. SGLT 1 has a higher affinity but low concentration (with 2:1 sodium-glucose co - transport ratio), thus causing only 10 % of total glucose reabsorption; while, SGLT 2 has higher concentration (with 1:1 sodium-glucose co - transport ratio) with 90 % of total glucose reabsorption. Selective inhibition of SGLT 2 transport proteins reduces reabsorption rate of glucose molecule resulting in an increase in the glucose excretion rate and reduction in the blood glucose concentration to 40 - 120 mg / dL, and this is beneficially effective for treating diabetes mellitus type II. The functions (rather than glucose absorption) of SGLT1 in the large intestine is presently under investigation, but it is observed that the inhibition of SGLT1 produces the intestinal complications like diarrhea, which disturbs the wellness of large intestine.

The clinical benefits of SGLT - 2 inhibitors are improved glucose control, faster metabolic effect, weight loss, significant reduction in blood pressure, cardiovascular benefits, and reduced sympathetic over activity. Remogliflozin etabonate (RE), an oral prodrug of remogliflozin, is a selective sodium-glucose co-transporter subtypes 2 (SGLT2) inhibitor, having anti - hyperglycemic activity, which is used in the treatment of diabetes mellitus type 2. Remogliflozin etabonate could be an effective oral adjunct to insulin for the treatment of type 1 diabetes. Remogliflozin etabonate has a water solubility of 0.189 mg/ml, and it is a proposed drug for the treatment of non-alcoholic steatohepatitis and type 2 diabetes. Remogliflozin etabonate significantly increases urinary glucose excretion and reduces plasma glucose concentration.^{1, 5}

Remogliflozin is administered in the prodrug form, that is, remogliflozin etabonate (RE) in an immediate release (IR) tablet formulation. Different doses of remogliflozin of 20 mg, 50 mg, 100 mg, 150 mg, 500 mg, and 1000 mg, with varying daily drug intake schedules, are being investigated.^{1, 6, 7} After administration, RE is de - esterified by non - specific esterases present in the mucosal cells of the gastrointestinal tract and converted into its active form remogliflozin. RE is rapidly and almost completely absorbed, with availability in the plasma within 10 minutes with a Tmax of 0.5 – 1 hour. The administration with standard breakfast slightly delayed the Tmax by approximately 0.5 – 1.5 hours; without any significant difference in the Cmax or Area Under Curve (AUC) relative to the fasting state. Hence RE can be administered with or without food. The plasma protein binding of remogliflozin was around 65 %. Either RE or remogliflozin was not preferentially distributed to blood cells, and there was no selective association of RE or its metabolites with melanin containing tissues. In the systemic circulation,

remogliflozin is extensively metabolized, leading to N - dealkylation, O - dealkylation, oxidation, loss of glucose, and glucuronidation. In vitro studies have demonstrated that the primary enzyme involved in the CYP - based metabolism of remogliflozin is CYP3A4, with a minor contribution from CYP2C19. Remogliflozin gets metabolized to two active metabolites, namely: GSK279782 and GSK333081. The major active metabolite GSK279782 has been shown to account for approximately 16 - 22 % of the concentration of remogliflozin in circulation. The exposure of GSK333081 was found to be extremely low after single - dose studies and hence not considered clinically significant. Remogliflozin has multiple pathways of elimination, like CYP and non - CYP pathways. The mean plasma elimination half-life of remogliflozin and GSK 279782 were around 1.5 to 1.9 hours and 2.3 to 3.8 hours, respectively, in healthy volunteers after a single dose of RE at 100 mg or 250 mg. In the same study, the mean plasma half - life of prodrug was mostly around 0.4 hours to 0.7 hours. Metabolic products of RE are eliminated from the body through renal excretion. In several radio-labelled absorption, metabolic, and excretion (AME) studies, approximately 93 % was excreted in the urine, with 11 % of the dose being recovered as remogliflozin in urine; and the majority of drug - related material is eliminated via the urine as inactive glucuronide metabolites. On the evaluation of the inhibitory concentration of remogliflozin, it was demonstrated that K_i values were 12.4 and 4520 nmol / l for SGLT2 and SGLT1, respectively. This shows that remogliflozin is a selective inhibitor of SGLT2.^{1,2}

The adverse effects of SGLT2 inhibitor drugs include diabetic ketoacidosis, bone fracture, urinary tract infection, genital fungal infection, foot and toe amputation, breast cancer, Leydig cell tumour and bladder cancer.^{1,5}

In this study, among 125 new type II diabetes mellitus patients, of early moderate grade, receiving metformin monotherapy for 1 month, 25 diabetic patients: (i) Who had achieved adequate glycaemic control with metformin monotherapy, or (ii) Who were lost to follow-up, or (iii) Who had dropped out due to adverse effects, or (iv) Who had withdrawn voluntarily, were excluded from the study. The remaining 100 patients, whose glycaemic index was uncontrolled by metformin monotherapy, received 50 mg remogliflozin with 500 mg metformin combination therapy once daily, for 15 days, and subsequently 75 mg remogliflozin with 500 mg metformin combination therapy once daily, for 15 days. These patients had completed the study thoroughly, with no adverse effects related drop - out patients, lost to follow-up patients or voluntarily withdrawn patients. The demographic characteristics of the patients were comparable. The combination therapies of increasing doses of remogliflozin and metformin were observed to be safe, and they have controlled type II diabetes mellitus among new patients, with significant decrease in the blood sugar levels and the HbA1c levels, within 2 months. This supports the successful synergistic effect of these anti-diabetic combination therapies, with a gradually increasing dose of remogliflozin. There were no adverse effects observed with the combination therapies of 50 mg or 75 mg of remogliflozin with metformin, which were statistically non - significant. The combination therapies of 50 mg or 75 mg remogliflozin with metformin were observed to be safe and tolerable. The results showed a significant decrease in the occurrence of adverse effects associated with these combination therapies, which were quite beneficial in the treatment of diabetes mellitus type II patients. All the global patients were satisfied with the different attributes of anti-diabetic tertiary medical healthcare provided, like immediate treatment delivery,

appropriate convenient investigations and treatment, quickly controlled diabetes, safe and tolerable treatment, and early accessible medications, convenient administration of medications and maintenance of symptom-free controlled diabetic period.

A single dose, dose - escalation study in healthy human volunteers, and T2DM patients observed 24 - hour urine glucose excretion (UGE) to be 17.5 - 40.5g and 66.6 to 112.6g, respectively, in a dose-dependent manner. The UGE showed a dose - dependent increase in total urine glucose excretion (UGE) from 0 to 24 hours in fasted and fed conditions. However, UGE increased less proportionally with an increase in dose from 150 mg to 500 mg, indicating a plateau effect, as observed with drugs of this class. Urinary glucose excretion was higher in patients with T2DM than in volunteers because of higher plasma glucose concentrations in patients. On correcting the UGE according to circulating plasma glucose concentrations and creatinine clearance, to estimate the percentage filtered glucose load, it was found to be similar in both healthy individuals as well as T2DM patients. Clinically significant increases in UGE and urine volumes were observed in 12 - week dose - ranging (50 - 1000 mg) study in drug naïve T2DM patients. A dose ordered increase at 12 weeks from baseline was observed in UGE over 24 hours ranging from 61 to 96 g / day. A similar dose-ordered increase at 12 weeks in urine volume was observed (~0.5L / day). The key pharmacokinetic and pharmacodynamic studies that assisted the characterization of clinical profiles were also significant.^{1,2}

Therefore, this study suffices its objective, amply assessing the globally relevant prescribing rationale of diabetological pharmacotherapeutic application, along with the safety evaluation of the anti - diabetic combination therapies with subsequent increase in drug doses of 50 mg, and then, 75 mg remogliflozin with 500 mg metformin, in type II diabetes mellitus patients, in tertiary care medical college hospitals. This type of stepwise increase in a single drug dose within a combination therapy potentiates the effective evidence - based selective pharmacotherapeutic response of the diabetic patients to gradual modification of the combination regimens; thereby also focusing on the minimalization of adverse effects of anti - diabetic drugs along with effective clinical responses, shown even with lowered doses of a single drug in the prescribed combination drug regimens.

CONCLUSION

This study established that the combination therapies consisting of the increasing doses of remogliflozin 50 mg or 75 mg, along with 500 mg metformin, were safe and tolerable. All the patients were satisfied with each anti - diabetic medical healthcare attribute. This study would remain a significant landmark towards the determination of precisely adjusted dose schedules of anti - diabetic singular drug regimen or combination drug regimens, each dose being specifically titrated in accordance with the investigative and evidence - based pharmacotherapeutic effectiveness and clinical response of the diabetic patient, emphasized further by the significant authentication of drug efficacy and safety.

REFERENCES

- [1] Hazra M. An endocrinological pharmacovigilance study on the safety assessment of metformin monotherapy

- and the combination therapy of remogliflozin with metformin, in the new type II diabetes mellitus patients, in tertiary care medical college hospitals. *World J Pharm Res.* 2021; 10 (11): 1443-1453. [Crossref], [Google Scholar]
- [2] Mohan V, Mithal A, Joshi SR, et al. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. *Drug Des Devel Ther.* 2020; 14: 2487–2501. [Crossref], [Google Scholar]
- [3] American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2021. *Diabetes Care.* 2021; 44 (Suppl. 1): S111–S124. [Crossref], [Google Scholar]
- [4] LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. *Endocr Rev.* 2021; 42 (1): 77–96. [Crossref], [Google Scholar]
- [5] Tiwari SS, Wadher SJ, Fartade SJ, et al. Gliflozin a new class for type-II diabetes mellitus: an overview. *Int J Pharm Sci Res.* 2019; 10 (9): 4070-4077. [Crossref], [Google Scholar]
- [6] Kapur A, O'Connor-Semmes R, Hussey EK, et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. *BMC Pharmacol Toxicol.* 2013; 14: 26. [Crossref], [Google Scholar]
- [7] Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes. *Diabetes Care.* 2012; 35(11): 2198-2200. [Crossref], [Google Scholar]